DNA vs KMDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.
KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.
Compare Another Pair
Related Comparisons
DNA vs KMDA: Head-to-Head Comparison
This page compares Ginkgo Bioworks Holdings, Inc. (DNA) and Kamada Ltd. (KMDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.